Alpelisib
Piqray (alpelisib) is a small molecule pharmaceutical. Alpelisib was first approved as Piqray on 2019-05-24. It is used to treat breast neoplasms and male breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform. In addition, it is known to target phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform, and phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform. Piqray's patents are valid until 2030-09-28 (FDA).
Trade Name | Piqray |
---|---|
Common Name | Alpelisib |
Indication | breast neoplasms, male breast neoplasms |
Drug Class | Phosphatidylinositol 3-kinase inhibitors |